Global Ischemic Heart Disease (IHD)Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Ischemic Heart Disease (IHD)Drugs Market Research Report 2024
Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.
According to Mr Accuracy reports’s new survey, global Ischemic Heart Disease (IHD)Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Ischemic Heart Disease (IHD)Drugs market research.
Ways to reduce CAD risk include eating a healthy diet, regularly exercising, maintaining a healthy weight, and not smoking. Medications for diabetes, high cholesterol, or high blood pressure are sometimes used. Additional medications such as antiplatelets, beta blockers, or nitroglycerin may be recommended.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ischemic Heart Disease (IHD)Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AstraZeneca
Bayer
Eli Lilly
Novartis
Pfizer
Sanofi
Segment by Type
Antidyslipidemic Drugs
Calcium Channel Blockers
Beta-blockers
ACE Inhibitors
Vasodilators
Antithrombotic Agents
Others
Segment by Sales Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Ischemic Heart Disease (IHD)Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Sales Channel)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Sales Channel Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Ischemic Heart Disease (IHD)Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Ischemic Heart Disease (IHD)Drugs market research.
Ways to reduce CAD risk include eating a healthy diet, regularly exercising, maintaining a healthy weight, and not smoking. Medications for diabetes, high cholesterol, or high blood pressure are sometimes used. Additional medications such as antiplatelets, beta blockers, or nitroglycerin may be recommended.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ischemic Heart Disease (IHD)Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca
Bayer
Eli Lilly
Novartis
Pfizer
Sanofi
Segment by Type
Antidyslipidemic Drugs
Calcium Channel Blockers
Beta-blockers
ACE Inhibitors
Vasodilators
Antithrombotic Agents
Others
Segment by Sales Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Ischemic Heart Disease (IHD)Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Sales Channel)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Sales Channel Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices